Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis

Frontiers In Cardiovascular Medicine

by Yanbo Wang, Lifang Su, Qing Zhou, Jia Tian, Wei Zhi, Yang Fu, Qing Wang, Yunfa Jiang, Xinshun Gu
May 28, 2026

Nature Medicine

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants

by Nicholas A. Marston, Shinwan Kany, Giorgio E. M. Melloni, Sean J. Jurgens, Frederick K. Kamanu, Yi-Pin Lai, Joel T. Rämö, Itamar Raz, Stephen D. Wiviott, Patrick T. Ellinor, Marc S. Sabatine, Christian T. Ruff
June 8, 2026

Conexiant

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

by Kathryn Wighton
June 11, 2026
2 min

Frontiers In Cardiovascular Medicine

Prediction model for early left ventricular systolic dysfunction progression in hypertrophic cardiomyopathy

by Yu Li, Ziqi Duan, Jinlei Li, Bingxin Cheng, Fen Ai, Zhen Chen
June 12, 2026

Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis

Original Source(s)

Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis

Related Content

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants

When Bad Data Enters the Drug Pipeline

Prediction model for early left ventricular systolic dysfunction progression in hypertrophic cardiomyopathy